New CEO for University of Cambridge spin-out Psyomics
Psyomics, a Cambridge University spin-out developing technology to support earlier and improved mental health diagnosis and treatment management, has appointed a new CEO.
Stephanie Martlew joins Psyomics to help align the company to strong potential market areas, facilitating its strategic shift from research to commercialisation. She brings a wealth of specialist knowledge in commercialising transformative mental health products as well as scaling health technology startups across international markets.
She has previously held leadership positions within two notable UK based mental health technology companies, supporting both from early-stage startup to fast growing scale-up.
Martlew said: “Psyomics’ product, Censeo, is novel and has potential to bring great value to the mental health industry. I am convinced that Censeo will be able to benefit both those looking to improve their mental health and the hugely stretched service providers who do their best every day to provide high quality care.
“Having spoken to the team and investors, I am confident that the technology, timing and culture is there to make a tremendous impact.”
While at virtual reality technology start-up Oxford VR, Martlew managed global operational and commercial activity at director level. Her success includes developing and mobilising a series of large-scale commercial contracts across the UK, US, Asia and Europe.
As one of the founding members of Ieso Digital Health (formerly PsychologyOnline), she helped the company expand across the NHS, before developing further growth areas outside of the UK which included replicating the business in the US.
Psyomics was founded by Professor Sabine Bahn, head of Cambridge Centre for Neuropsychiatric Research and a practising NHS psychiatrist.